Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2023-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples

NCT02239575

Cancer

WITHDRAWN

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ann Arbor Stage I Lymphoma +59 more

RECRUITING

Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

NCT05585684

Solid Tumor

RECRUITING

Collection of Tissue Blocks or Slides From Patients With Cancer

NCT02810405

Tumor Carcinogens Neoplasm, Benign +2 more

COMPLETED

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

NCT05600933

Solid Tumors Hematologic Malignancy Gastrointestinal Cancer +5 more

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll subjects diagnosed with various cancers and who are scheduled to undergo surgical treatment. Prior to scheduled surgery, subjects will be asked to donate a 10-20 ml blood sample. After surgery, surplus tissues (including tumor and adjacent normal tissues) not required for diagnosis will be collected. Subject clinical information will be collected, including basic demographic information, medical history, family history, current cancer history and treatment. After surgery, a final pathology report will be obtained for each subject's surgical specimen. In some instances and based on the cancer indications required, longitudinal data may also be collected at a frequency of every 6 months to once per year. Longitudinal data will include information on study subject survival and disease recurrence.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer Hematologic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer Subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any adult age
* Any sex
* Able to provide consent for surplus tissue and/or blood donation
* Diagnosed with one of the cancer indications listed below:
* Scheduled to undergo surgical resection of tumor (exception for hematological cancers)
* Have not yet received treatment for cancer

Exclusion Criteria

* Not diagnosed with required cancer indication
* Not scheduled to undergo surgical resection of the tumor
* Have already received cancer treatment (such as chemotherapy, radiation, surgery) for the current cancer or a previously diagnosed cancer
* Not able to donate an adequate volume of blood to meet minimum requirements

CANCER INDICATIONS:

1. Bladder Cancer - Urothelial carcinoma - nonpapillary
2. Bladder Cancer - Urothelial carcinoma - papillary
3. Brain Cancer - Astrocytoma
4. Brain Cancer - Glioblastoma
5. Brain Cancer - Medulloblastoma
6. Breast Cancer - Ductal Carcinoma
7. Breast Cancer - Lobular Carcinoma
8. Cervical Cancer - Squamous Cell Carcinoma
9. Colorectal Cancer - Adenocarcinoma
10. Esophageal Cancer - Adenocarcinoma
11. Gastric Cancer
12. Head and Neck Cancer - Squamous Cell Carcinoma
13. Hematologic Cancer - Acute Lymphocytic Leukemia (ALL)
14. Hematologic Cancer - Acute Myeloid Leukemia (AML)
15. Hematologic Cancer - Chronic Lymphocytic Leukemia (CLL)
16. Hematologic Cancer - Diffuse Large B-cell Lymphoma
17. Hematologic Cancer - Multiple Myeloma (MM)
18. Hematologic Cancer - Non-Hodgkins Lymphoma (NHL)
19. Kidney Cancer - Papillary Carcinoma
20. Kidney Cancer - Renal cell Carcinoma
21. Liver Cancer - Hepatocellular Carcinoma
22. Lung Cancer - Adenocarcinoma
23. Lung Cancer - Squamous Cell Cancer
24. Melanoma
25. Pancreatic Cancer - Ductal Adenocarcinoma
26. Prostate Cancer - Adenocarcinoma
27. Sarcomas
28. Thyroid Cancer - Follicular Carcinoma
29. Thyroid Cancer - Papillary Carcinoma
30. Uterine Cancer - Endometrial Carcinoma

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No